Year: 2017
Type: review
Abstract: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ) in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum, including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by neurodegeneration of the striosome and matrix compartments, leading to progressive impairment of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still unknown; however, accumulating clinical and experimental evidence suggests multiple plausible pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity and neuroprotection.
Source: Brain Sciences
Authors: Ryoma Morigaki, Satoshi Goto
Institutions: Tokushima University Hospital, Tokushima University
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,654
Awards: G2204392343, Development of new surgical therapies for l-dopa induced dyskinesia targeting striatal striosome comparment, G3146557907, G3876266209, Development of a new therapy for L-dopa-induced dyskinesia in Parkinson's disease targeting nuclear factor kappa b, Experimental study on functional pathology of dystonia, Disease- and Deep Brain Stimulation-Related Metabolic Networks using FDG-PET in Movement disorders, Research on molecular pathogenesis and next-generation therapeutic agent for dystonia-parkinsonism, Experimental study on functional pathology of L-DOPA-induced dyskinesia in Parkinson's disease., G8850162180
OpenAlex ID: W2621530723
